Quantitative flow ratio versus fractional flow reserve for guiding percutaneous coronary intervention: design and rationale of the randomised FAVOR III Europe Japan trial.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
03 Apr 2023
Historique:
pmc-release: 03 04 2024
medline: 10 4 2023
pubmed: 18 1 2023
entrez: 17 1 2023
Statut: epublish

Résumé

Quantitative flow ratio (QFR) is a computation of fractional flow reserve (FFR) based on invasive coronary angiographic images. Calculating QFR is less invasive than measuring FFR and may be associated with lower costs. Current evidence supports the call for an adequately powered randomised comparison of QFR and FFR for the evaluation of intermediate coronary stenosis. The aim of the FAVOR III Europe Japan trial is to investigate if a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with a standard FFR-guided strategy in the evaluation of patients with intermediary coronary stenosis. FAVOR III Europe Japan is an investigator-initiated, randomised, clinical outcome, non-inferiority trial scheduled to randomise 2,000 patients with either 1) stable angina pectoris and intermediate coronary stenosis, or 2) indications for functional assessment of at least 1 non-culprit lesion after acute myocardial infarction. Up to 40 international centres will randomise patients to either a QFR-based or a standard FFR-based diagnostic strategy. The primary endpoint of major adverse cardiovascular events is a composite of all-cause mortality, any myocardial infarction, and any unplanned coronary revascularisation at 12 months. QFR could emerge as an adenosine- and wire-free alternative to FFR, making the functional evaluation of intermediary coronary stenosis less invasive and more cost-effective.

Identifiants

pubmed: 36648404
pii: EIJ-D-21-00214
doi: 10.4244/EIJ-D-21-00214
pmc: PMC10068862
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1358-e1364

Auteurs

Birgitte Krogsgaard Andersen (BK)

Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.

Martin Sejr-Hansen (M)

Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.

Jelmer Westra (J)

Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.

Gianluca Campo (G)

Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy and Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA), Italy.

Ashkan Efterkhari (A)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Shengxian Tu (S)

School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.

Javier Escaned (J)

Hospital Clinico San Carlos IdISSC, Complutense University of Madrid, Madrid, Spain.

Lukasz Koltowski (L)

Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Barbara E Stähli (BE)

Department of Cardiology, University Heart Center, University Hospital Zürich, Zürich, Switzerland.

Andrejs Erglis (A)

Department of Cardiology, Riga Stradiņš University, Riga, Latvia.

Gediminas Jaruševičius (G)

Department of Cardiology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania and Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Greta Žiubrytė (G)

Department of Cardiology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania and Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Truls Råmunddal (T)

Department of Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden.

Tommy Liu (T)

Department of Cardiology, HagaZiekenhuis, The Hague, the Netherlands.

William Wijns (W)

The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, Ireland.

Ulf Landmesser (U)

Department of Cardiology (CBF), Charite - Universitätsmedizin Berlin, Berlin, Germany.

Luc Maillard (L)

GCS ES Axium Rambot, Clinique Axium, Aix-en-Provence, France.

Hitoshi Matsuo (H)

Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.

Evald Høj Christiansen (EH)

Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.

Niels Ramsing Holm (NR)

Department of Cardiology, Aarhus University Hospital, Skejby, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH